BRIEF-Scholar Rock Highlights 2025 Strategic Priorities

Reuters05:10

Jan 8 (Reuters) - Scholar Rock Holding Corp SRRK.O:

SCHOLAR ROCK HIGHLIGHTS 2025 STRATEGIC PRIORITIES
SCHOLAR ROCK HOLDING CORP -FILING OF IND APPLICATION FOR SRK-439 ON TRACK FOR 3Q 2025
SCHOLAR ROCK HOLDING CORP - BLA AND MAA SUBMISSION FOR APITEGROMAB IN SMA ON TRACK FOR 1Q 2025
SCHOLAR ROCK HOLDING CORP - INITIATING PHASE 2 OPAL TRIAL IN SMA PATIENTS UNDER TWO YEARS OLD IN MID- 2025
SCHOLAR ROCK HOLDING CORP - DATA FROM PHASE 2 EMBRAZE TRIAL EXPECTED IN 2Q 2025

Source text: ID:nBwbcTM0Ha

Further company coverage: SRRK.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2502515083?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-09 05:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2502515083","market":"us","top_or_hot":-1,"title":"BRIEF-Scholar Rock Highlights 2025 Strategic Priorities","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Scholar Rock Highlights 2025 Strategic Priorities</title></head><body><p><span>Jan 8 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/SRRK\">Scholar Rock Holding Corp</a> <span>SRRK.O</span>:</p><ul><li><p>SCHOLAR ROCK HIGHLIGHTS 2025 STRATEGIC PRIORITIES</p></li><li><p>SCHOLAR ROCK HOLDING CORP -FILING OF IND APPLICATION FOR SRK-439 ON TRACK FOR 3Q 2025</p></li><li><p>SCHOLAR ROCK HOLDING CORP - BLA AND MAA SUBMISSION FOR APITEGROMAB IN SMA ON TRACK FOR 1Q 2025</p></li><li><p>SCHOLAR ROCK HOLDING CORP - INITIATING PHASE 2 OPAL TRIAL IN SMA PATIENTS UNDER TWO YEARS OLD IN MID- 2025</p></li><li><p>SCHOLAR ROCK HOLDING CORP - DATA FROM PHASE 2 EMBRAZE TRIAL EXPECTED IN 2Q 2025</p></li></ul><p>Source text: <span>ID:nBwbcTM0Ha</span></p><p>Further company coverage: <span>SRRK.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Scholar Rock Highlights 2025 Strategic Priorities</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Scholar Rock Highlights 2025 Strategic Priorities\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-09 05:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250108:nTUA58K487:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BRIEF-Scholar Rock Highlights 2025 Strategic PrioritiesJan 8 (Reuters) - Scholar Rock Holding Corp SRRK.O:SCHOLAR ROCK HIGHLIGHTS 2025 STRATEGIC PRIORITIESSCHOLAR ROCK HOLDING CORP -FILING OF IND ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250108:nTUA58K487:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250108:nTUA58K487:1","article_id":"2502515083","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2502515083","pubTimestamp":1736370655,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Scholar Rock Highlights 2025 Strategic PrioritiesJan 8 (Reuters) - Scholar Rock Holding Corp SRRK.O:SCHOLAR ROCK HIGHLIGHTS 2025 STRATEGIC PRIORITIESSCHOLAR ROCK HOLDING CORP -FILING OF IND APPL","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SRRK":"Scholar Rock Holding Corp"},"translate_title":"简介-Scholar Rock强调2025年战略重点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SRRK":0.9},"content_text":"BRIEF-Scholar Rock Highlights 2025 Strategic PrioritiesJan 8 (Reuters) - Scholar Rock Holding Corp SRRK.O:SCHOLAR ROCK HIGHLIGHTS 2025 STRATEGIC PRIORITIESSCHOLAR ROCK HOLDING CORP -FILING OF IND APPLICATION FOR SRK-439 ON TRACK FOR 3Q 2025SCHOLAR ROCK HOLDING CORP - BLA AND MAA SUBMISSION FOR APITEGROMAB IN SMA ON TRACK FOR 1Q 2025SCHOLAR ROCK HOLDING CORP - INITIATING PHASE 2 OPAL TRIAL IN SMA PATIENTS UNDER TWO YEARS OLD IN MID- 2025SCHOLAR ROCK HOLDING CORP - DATA FROM PHASE 2 EMBRAZE TRIAL EXPECTED IN 2Q 2025Source text: ID:nBwbcTM0HaFurther company coverage: SRRK.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"event","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2502515083"}